Sinai Hospital Of Baltimore | ClinicalTrials HQ

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)	Arterial Occlusive Diseases, Chronic Disease, Death, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Urogenital Diseases, arteriosclerosis disorder, atherosclerosis, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, chronic renal failure syndrome, coronary artery disorder, diabetes mellitus, endocrine system disorder, glucose metabolism disease, heart disorder, kidney disorder, kidney failure, metabolic disease, myocardial ischemia, nervous system disorder, peripheral arterial disease, peripheral vascular disease, type 2 diabetes mellitus, urinary system disorder, vascular disorder	Active, not recruiting	Phase 3	2026-10-08		NCT06383390
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, vascular disorder	Active, not recruiting	Phase 3	2026-10-08		NCT06292013
A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2	cardiovascular disorder, hypertensive disorder, vascular disorder	Active, not recruiting	Phase 3	2026-05-29		NCT06952530
A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)	cardiovascular disorder, hypertensive disorder, vascular disorder	Active, not recruiting	Phase 3	2026-05-29		NCT06948422